TATX-112 / ImmunoPrecise - LARVOL DELTA

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies (Businesswire) - "ImmunoPrecise Antibodies Ltd...is proud to announce a significant breakthrough in its primary cancer research initiatives. This accomplishment not only highlights IPA’s cutting-edge discovery and AI capabilities, but it also strategically places the company in the rapidly growing market for these cancer-combating antibodies, which is projected to reach $20.7 billion by 2028. The TATX-112 program, dedicated to the development of specialized antibodies for cancer treatment, has shown encouraging results, successfully targeting cells that express a protein known as TrkB. This achievement has paved the way for several promising candidates for further development....The TATX-200 program is centered on developing T cell engagers, which boost the body's immune response against tumors."

Commercial • Oncology • Solid Tumor

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease (Businesswire) - "IMMUNOPRECISE ANTIBODIES...today announced that its subsidiary Talem Therapeutics LLC ('Talem') has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112...In addition to TATX-112, Talem is continuing development efforts of its other potential products leveraging its pipeline of highly differentiated therapeutic antibody programs for the potential treatment of...cancer."

New trial • Oncology